Agents tageting small interfering RNAs (siRNA) for use in cancer have been developed. The phase 1 clinical trials are over and the results were recently published in Nature.
CALAA-01 is a nanoparticle drug containing small interfering RNAs targeted to ribonucleside reductase M2. This is used in solid tumors that are refractory to therapy.
This opens an entirely new class of anticancer agents.
7 years ago
Posts
